Biotech News
Ouro Medicines Launches with $120M Funding to Advance Immune Reset Therapies
Ouro Medicines has officially launched with $120 million in funding to develop immune reset therapeutics for chronic immune-mediated diseases. The Series A funding round was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with additional support from
17 January 2025
Stay ahead of trends and best practices
